Directory
Portfolio companies.
21,000+ PE-backed.
Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.
Active deals
919
currently held
Exits tracked
338
hand-checked
Sectors covered
1
across the portfolio
Countries covered
35
from every market
1,150 companies matching · Page 16 of 23
AmSilk
Athos Evergreen Life Sciences
GermanySector
Biotech
InvestorAthos
Entry
2008
Hold
18yr
Owners
3
Asgard Therapeutics
Boehringer Ingelheim Venture Fund
SwedenSector
Biotech
InvestorBoehringer Ingelheim Venture Fund
Entry
2021
Hold
5yr
Owners
3
BIONYRA PHARMA
Jeito II
FranceSector
Biotech
InvestorJeito Capital
Entry
2025
Hold
1yr
Owners
3
Bluu Seafood
LBBW VC Evergreen Vehicle
GermanySector
Biotech
InvestorLBBW Venture Capital
Entry
2020
Hold
6yr
Owners
3
Dania Therapeutics
Lundbeckfonden BioCapital
DenmarkSector
Biotech
InvestorLundbeckfonden BioCapital
Entry
2023
Hold
3yr
Owners
3
EvlaBio
AFB Fund II
FranceSector
Biotech
InvestorAdBio Partners
Entry
2025
Hold
1yr
Owners
3
Formo
SevenVentures Media-for-Equity
GermanySector
Biotech
InvestorSevenVentures
Entry
2019
Hold
7yr
Owners
3
Generare
Daphni Blue
FranceSector
Biotech
InvestorDaphni
Entry
2024
Hold
2yr
Owners
3
Hoba Therapeutics
EIFO (direct equity)
SwitzerlandSector
Biotech
InvestorEifo
Entry
2022
Hold
4yr
Owners
3
Kebony
Health for Life Capital
NorwaySector
Biotech
InvestorSeventure Partners
Entry
2021
Hold
5yr
Owners
3
NeoPhore
Neva First
United KingdomSector
Biotech
InvestorNeva SGR
Entry
2021
Hold
5yr
Owners
3
Pacifico Biolabs
Simon Capital Evergreen
GermanySector
Biotech
InvestorSimon Capital
Entry
2024
Hold
2yr
Owners
3
Strike Pharma
Flerie Invest
SwedenSector
Biotech
InvestorFlerie
Entry
2021
Hold
5yr
Owners
3
Tribune Therapeutics
LifeArc Ventures
SwedenSector
Biotech
InvestorLifeArc
Entry
2021
Hold
5yr
Owners
3
Accure Therapeutics
Sabadell Asabys Health Innovation Investments
SpainSector
Biotech
InvestorAsabys Partners
Entry
2020
Hold
6yr
Owners
2
AdvanCell
Abingworth Bioventures 8
Australia
Sector
Biotech
InvestorAbingworth
Entry
2025
Hold
1yr
Owners
2
Antag Therapeutics
EIFO (direct equity)
DenmarkSector
Biotech
InvestorEifo
Entry
2017
Hold
9yr
Owners
2
Ariceum Therapeutics
Earlybird Health
GermanySector
Biotech
InvestorEarlybird Venture Capital
Entry
2022
Hold
4yr
Owners
2
Asceneuron
Novo Holdings Venture Investments
FranceSector
Biotech
InvestorNovo Holdings
Entry
2020
Hold
6yr
Owners
2
Atlas Bio
LEA Venturepartner (VC)
SwitzerlandSector
Biotech
InvestorLEA Partners
Entry
2024
Hold
2yr
Owners
2
Aviwell
Elaia Legacy Fund
FranceSector
Biotech
InvestorLazard Elaia Capital
Entry
2022
Hold
4yr
Owners
2
Bactolife
EIFO (direct equity)
DenmarkSector
Biotech
InvestorEifo
Entry
2021
Hold
5yr
Owners
2
Basic Genomics
Segulah Medical Acceleration
SwedenSector
Biotech
InvestorSegulah Medical Acceleration
Entry
2025
Hold
1yr
Owners
2
Booster Therapeutics
Apollo Health Ventures Fund II
GermanySector
Biotech
InvestorApollo Health Ventures
Entry
2024
Hold
2yr
Owners
2
Cambrium
Redstone Ventures
GermanySector
Biotech
InvestorRedstone
Entry
2020
Hold
6yr
Owners
2
cAMPfield
Novo Holdings Seed Investments
USSector
Biotech
InvestorNovo Holdings
Entry
2026
Hold
0yr
Owners
2
Captain T Cell GmbH
Technologiegründerfonds Sachsen
GermanySector
Biotech
InvestorCFH Management
Entry
2024
Hold
2yr
Owners
2
COLIPI
HTGF IV
GermanySector
Biotech
InvestorHigh-Tech Gruenderfonds (HTGF)
Entry
2024
Hold
2yr
Owners
2
CPTx
BlueYard Capital Fund III
GermanySector
Biotech
InvestorBlueYard Capital
Entry
2024
Hold
2yr
Owners
2
Flash Therapeutics
TechLife Capital II
FranceSector
Biotech
InvestorTechLife Capital
Entry
2016
Hold
10yr
Owners
2
Gamamabs Pharma
IRDI Impulsion
FranceSector
Biotech
InvestorIrdi Capital-Investissement
Entry
2013
Hold
13yr
Owners
2
Graph Therapeutics
SquareOne III
AustriaSector
Biotech
InvestorSquareOne
Entry
2024
Hold
2yr
Owners
2
GutCRINE
Eir Ventures I
DenmarkSector
Biotech
InvestorEir Ventures
Entry
2023
Hold
3yr
Owners
2
Hillstar Bio
LifeArc Ventures
United StatesSector
Biotech
InvestorLifeArc
Entry
2023
Hold
3yr
Owners
2
hutchmed
Carlyle Asia Partners III
China
Sector
Biotech
InvestorThe Carlyle Group
Entry
–
Owners
2
IAMA Therapeutics
Indaco BIO
ItalySector
Biotech
InvestorIndaco Venture Partners SGR
Entry
2022
Hold
4yr
Owners
2
iDEL Therapeutics
Gruenderfonds Ruhr II
GermanySector
Biotech
InvestorGruenderfonds Ruhr
Entry
2025
Hold
1yr
Owners
2
Imperagen
IQ Capital Fund IV
UKSector
Biotech
InvestorIQ Capital Partners
Entry
2022
Hold
4yr
Owners
2
IMU Biosciences
IQ Capital Fund IV
UKSector
Biotech
InvestorIQ Capital Partners
Entry
2024
Hold
2yr
Owners
2
LEV2050
Stellum Food & Tech I
SpainSector
Biotech
InvestorStellum Capital
Entry
2024
Hold
2yr
Owners
2
Melt&Marble
Oscar & Paul Venture Capital Fund I
SwedenSector
Biotech
InvestorOscar & Paul (Beiersdorf Venture Capital)
Entry
2021
Hold
5yr
Owners
2
MOLECULAR ATTRACTION
Almi Invest GreenTech
SwedenSector
Biotech
InvestorAlmi Invest
Entry
2021
Hold
5yr
Owners
2
Monument Therapeutics
Angel CoFund
UKSector
Biotech
InvestorACF Investors
Entry
2024
Hold
2yr
Owners
2
NeRRe Therapeutics
Columbus Life Science Fund II
United KingdomSector
Biotech
InvestorColumbus Venture Partners
Entry
2021
Hold
5yr
Owners
2
Nosh.bio
CHECK24 Impact
GermanySector
Biotech
InvestorCHECK24 Ventures
Entry
2023
Hold
3yr
Owners
2
NRG Therapeutics
Criteria Bio Ventures
UKSector
Biotech
InvestorCaixa Capital Risc
Entry
2020
Hold
6yr
Owners
2
Nuritas
European Circular Bioeconomy Fund
IrelandSector
Biotech
InvestorECBF Management GmbH
Entry
2021
Hold
5yr
Owners
2
Nuvig Therapeutics
Leaps by Bayer
United StatesSector
Biotech
InvestorLeaps by Bayer
Entry
2022
Hold
4yr
Owners
2
Oblique Therapeutics
Sunstone Life Science Ventures IV
SwedenSector
Biotech
InvestorSunstone Life Science Ventures
Entry
2015
Hold
11yr
Owners
2
Octarine Bio
Footprint Fund I
DenmarkSector
Biotech
InvestorThe Footprint Firm
Entry
2023
Hold
3yr
Owners
2